Karyopharm Q1 net loss narrows

Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics, Inc.

KPTI

0.00


Overview

  • U.S. cancer therapy maker's net loss for Q1 narrowed, reflecting improved operating efficiency and disciplined cost management


Outlook

  • Karyopharm reaffirms 2026 total revenue guidance of $130 mln to $150 mln


Result Drivers

  • GROSS-TO-NET ADJUSTMENTS - Higher net product revenue was primarily driven by lower gross-to-net adjustments, including reduced discounts and product returns

  • COMPETITIVE PRESSURE - Demand for XPOVIO declined yr/yr due to new competitive entrants, according to the company

  • INTERNATIONAL ROYALTIES - Modest growth in royalty revenue from expanded global patient access and additional ex-U.S. approvals


Company press release: ID:nPn2Dhgsa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$22.39 mln

Q1 Operating Expenses

$61.83 mln

Q1 Operating Income

-$26.76 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 69.5% above its May 13 closing price of $8.85


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.